Can-Fite BioPharma Ltd.(CANF)Earnings, Financials & Key Ratios

The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseases Ramat Gan, Israel, June 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the Japan Patent Office has allowed Japanese Patent Application No.

The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseases

Ramat-Gan, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the publication of a peer-reviewed scientific article demonstrating the broad therapeutic potential of its lead drug candidates, Piclidenoson and Namodenoson, across multiple major diseases.

Company to Conduct Partnering Meetings Focused on Oncology, Liver Disease and Inflammatory Disease RAMAT GAN, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced its participation in the BIO International Convention 2026, to be held June 22–25, 2026, in San Diego, California.